about
Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean.Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the CaribbeanRates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy.Time to HAART Initiation after Diagnosis and Treatment of Opportunistic Infections in Patients with AIDS in Latin AmericaMonitoring of HIV treatment in seven countries in the WHO Region of the Americas.Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America NetworkHealth outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America.A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohorts.Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption.Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme.Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Wee[Evolution of epidemiological and clinical characteristics of adults patients belonging to the national program at start of antiretroviral therapy in the Chilean AIDS Cohort, 2001-2015].Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.[Clinical and epidemiological characteristics of HIV infection in Latin-American immigrants: comparative analysis from clinical records in a clinical care centre in Santiago in the last decade].Hepatitis B prevalence and influence on HIV treatment outcome and mortality in the Chilean AIDS Cohort.Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.Dual microsporidial infection with Encephalitozoon cuniculi and Enterocytozoon bieneusi in an HIV-positive patient.The Chilean AIDS cohort: a model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country--organization and preliminary results.Long-Term Outcomes of a National Expanded Access Program to Antiretroviral Therapy: The Chilean AIDS CohortUna década de terapia anti-retroviral: Perfil de pacientes con 10 años de triterapia de alta efectividadFalla de la profilaxis con cotrimoxazol para la neumonía por Pneumocystis jiroveci con el uso concomitante de leucovorina: Reporte de un casoPrimer caso de detección de blaKpc en Chile: desde Italia a un hospital público de SantiagoUse and Misuse of Antibiotics in Latin America
P50
Q28647212-2BD32A7C-E101-49BD-9D94-84CCDB8DC3E9Q28749991-5D486B86-1F10-498D-9811-D2C1C58E0B87Q33598309-888ABEFA-5C00-4B41-9C5F-18D6BE57A774Q33598309-B58DA060-8249-4ED4-A603-89CADAFB5EDFQ33834625-CD357F8A-2771-4BB3-B5C2-CC993C0E6232Q36043414-0D1064B4-632F-4FBF-8DF9-A398150899A1Q36089490-7D020059-67C3-4E1A-BD8E-E92C3D939EC6Q36462119-0353D3C6-CD70-49FB-ADB0-A106C9FB26B8Q36707987-5AB2E40A-23BC-4E35-8062-DD11CD790E35Q36768319-1B522E19-14F1-4ED2-829D-EEA8BBEC7FF4Q36889974-868FB094-BA33-4FCB-B4DF-A22C86D7ED52Q36936569-19A94C22-4E39-4AC3-A850-B2626B2A40C5Q38681264-4A0C38CF-A8EE-480B-AED0-29C6D981D30BQ39352442-E9634724-7DE2-4F26-8747-C34A313DFC19Q40223525-885E6B71-D555-4904-BA6B-C5DCD62C1073Q40480144-BF906A8A-F59D-4F0A-B827-02C92C944DD3Q41346555-B6D3EB9E-08BE-4D6A-95CA-87849954E80BQ42255344-C3336483-E7C5-4DD7-8B46-45F99D30EBE7Q42631309-49D74F3A-285B-410A-BAE0-9E4422117798Q43729928-DD6C3F10-3E5A-4B1B-AB47-FBAD39E4D489Q46801333-2260B00E-86C9-4356-96A8-F2562DBA9F53Q56786182-6977AF7A-A874-4D8A-8CAC-B0786464D7BFQ60997954-D9B99879-2B4B-428A-BD5B-B5CC9553A153Q60997955-B29D47C9-7336-4D22-81F6-723082E98EB1Q60997956-F01F5A64-C14B-47A3-8055-B257A9F00FB7Q60997958-D49F88C0-4827-41D9-A98C-A4A62C4417F8
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marcelo Wolff
@ast
Marcelo Wolff
@en
Marcelo Wolff
@es
Marcelo Wolff
@nl
Marcelo Wolff
@sl
type
label
Marcelo Wolff
@ast
Marcelo Wolff
@en
Marcelo Wolff
@es
Marcelo Wolff
@nl
Marcelo Wolff
@sl
prefLabel
Marcelo Wolff
@ast
Marcelo Wolff
@en
Marcelo Wolff
@es
Marcelo Wolff
@nl
Marcelo Wolff
@sl
P106
P1153
7403304592
P21
P31
P496
0000-0002-9956-8872